Abstract
Aberrant activation of protein kinase Cbeta (PKCbeta) by pancreatic cancer cells facilitates angiogenesis and tumor cell survival. Targeting PKCbeta with enzastaurin, a well-tolerated drug in clinical trials, would be expected to radiosensitize pancreatic tumors through direct antitumor and antivascular effects. We tested the hypothesis that enzastaurin radiosensitizes pancreatic cancer cells in culture and in vivo through inhibition of PKCbeta. We analyzed pancreatic cancer xenografts for growth delay and microvessel density after treatment with enzastaurin, radiation, or both. We determined the effect of radiation and enzastaurin on glycogen synthase kinase 3beta, a mediator of cell death in culture and in vivo. At concentrations attained in patients, enzastaurin reduced levels of active PKCbeta measured by phosphorylation at Thr(500) in culture and in xenografts. Enzastaurin alone did not affect pancreatic cancer cell survival, proliferation, or xenograft growth. However, enzastaurin radiosensitized pancreatic cancer cells in culture by colony formation assay. Enzastaurin alone decreased microvessel density of pancreatic cancer xenografts without appreciable effects on tumor size. When combined with radiation, enzastaurin increased radiation-induced tumor growth delay with a corresponding decrease in microvessel density. Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3beta at Ser(9) in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization. Enzastaurin inhibits PKCbeta in pancreatic cancer cells in culture, enhancing radiation cytotoxicity. Additional antivascular effects of enzastaurin were observed in vivo, resulting in greater radiosensitization. These results provide the rationale for a clinical trial in locally advanced pancreatic cancer combining enzastaurin with radiation.
Highlights
Aberrant activation of protein kinase Ch (PKCh) by pancreatic cancer cells facilitates angiogenesis and tumor cell survival
We have found that inhibition of PKCh with enzastaurin radiosensitizes pancreatic cancer cells in vitro and lengthens the duration of radiation-induced tumor growth delay in vivo
We found that human pancreatic cancer cell lines express active PKCh, and that treating these cells with enzastaurin at noncytotoxic concentrations achievable in patients produces modest radiosensitization in culture
Summary
Aberrant activation of protein kinase Ch (PKCh) by pancreatic cancer cells facilitates angiogenesis and tumor cell survival. Targeting PKCh with enzastaurin, a well-tolerated drug in clinical trials, would be expected to radiosensitize pancreatic tumors through direct antitumor and antivascular effects. Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3h at Ser in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization. Additional antivascular effects of enzastaurin were observed in vivo, resulting in greater radiosensitization These results provide the rationale for a clinical trial in locally advanced pancreatic cancer combining enzastaurin with radiation. PKCh activation promotes angiogenesis in endothelial cells surrounding tumor cells; the antivascular effects may potentiate the effects of radiation through normalization of tumor perfusion, restoring normoxia and increasing delivery of systemic agents. We tested the hypothesis that inhibition of PKCh with enzastaurin radiosensitizes pancreatic cancer cells in culture and in vivo
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.